Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-09-30 am EDT
44.55 HKD   -.--%
09/05China Regulator Includes CanSino's Inhalable COVID-19 Vaccine for Emergency Use; Shares Up More Than 9%
MT
09/04Cansino biologics inc set to open up 8.9% after its inhaled covi…
RE
09/04Cansino Biologics : CanSinoBIO's Convidecia Air™ Receives Approval in China
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CanSino Biologics : China announces first human trials of Covid-19 vaccine

03/18/2020 | 09:23am EDT

By Javier García

Beijing, Mar 18 (EFE).- China announced Wednesday that it had begun clinical human trials of a new coronavirus vaccine "successfully" developed by the Chinese Academy of Military Medical Sciences, although its mass production was still months away.

Just 19 hours after Washington announced it had started human trials for a Covid-19 vaccine, Beijing authorities unveiled their own tests and insisted they would produce the immunization quicker than the United States, according to the Global Times.

The media outlet, which falls under the umbrella of the People's Daily, the official organ of the Chinese Communist Party, warned that the vaccine would not be available to the general public for at least another 12 to 18 months.

It was nonetheless the first vaccine - of the many that have been researched - to go to the clinical trial stage of testing since Monday.

It is the product of a military science investigation led by top epidemiologist and general Chen Wei, who traveled to Wuhan, the epicenter of the virus outbreak, to research in collaboration with biotech company CanSino Biologics.

Chen is known in China for his work in 2014 developing the first vaccine in Asia - and the third in the world - against the Ebola virus.

According to Chinese media commentary, members of the military have the advantage in the search for a vaccine given they are not constrained by the same regulation as private companies.

"The epidemic is similar to a military situation. The epicenter is like the battleground," Chen told the local press.

Chen and his team installed themselves at the Wuhan Institute of Virology, the only center with level 4 biotechnology security clearance, the highest in Asia.

The vaccine has been submitted to safety and quality controls and is being prepared for mass production, a defense ministry statement said.

CanSino Biologics, based in the city of Tianjin, organized the volunteers for the clinical trial.

Imported Covid-19 cases continued to outstrip domestically-contracted cases in China for the fifth day in a row.

Officials on Wednesday reported 13 new infections, 12 of which had been brought into the country from other global hotspots.

As things stand, there have been 80,894 confirmed cases in China since the outbreak began. Some 11 died from Covid-19 Wednesday - all of them in central Hubei province - bringing the number of fatalities to 3,237, according to the National Health Commission.

Wuhan, the capital of Hubei, which has been in full lockdown since 23 January, is the worst-hit region in the world with 2,490 deaths. However, for the last two days, it has registered just one new infection - the only one transmitted locally in the entire country.

Until now, 69,601 people have recovered from the disease in China.

Earlier, Zhong Nanshan, the epidemiologist and pulmonologist leading the fight against coronavirus in China urged Europe to adopt more proactive measures, identify infections faster and to impose strict quarantines and restrictions.

"I believe Europe is facing the first round of the epidemic. I think they should take more proactive measures. Don't wait until it is very late and it hurts," Zhong said at a press conference in the southern city of Guangzhou.

China also announced Wednesday that it would expel US correspondents from The New York Times, The Wall Street Journal and the Washington Post a move that Beijing said had been carried out in the "spirit of reciprocity."

Those journalists will no longer be allowed to work in China, Hong Kong or Macau in a measure adopted not long after Washington ordered a reduction in the size of Chinese media outlets in the US. EFE

© 2020 EFE News Services (U.S.) Inc., source EFE Ingles

All news about CANSINO BIOLOGICS INC.
09/05China Regulator Includes CanSino's Inhalable COVID-19 Vaccine for Emergency Use; Shares..
MT
09/04Cansino biologics inc set to open up 8.9% after its inhaled covi…
RE
09/04Cansino Biologics : CanSinoBIO's Convidecia Air™ Receives Approval in China
PU
09/04CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergen..
CI
09/04CanSino's inhaled COVID-19 vaccine gets emergency use approval in China
RE
09/01UBS Adjusts CanSino Biologics' Price Target to HK$88 From HK$200, Keeps at Buy
MT
08/28Cansino biologics inc set to open down 6% after h1 revenue drop…
RE
08/28China's CanSinoBIO H1 revenue drops on weaker COVID shot demand
RE
08/26CanSino Biologics Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/18Cansino Biologics : Convidecia Air™ Receives Clinical Trial Approval in Malaysia
PU
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2022 1 477 M 208 M 208 M
Net income 2022 -371 M -52,1 M -52,1 M
Net cash 2022 4 977 M 700 M 700 M
P/E ratio 2022 -26,9x
Yield 2022 0,04%
Capitalization 19 184 M 2 697 M 2 697 M
EV / Sales 2022 9,62x
EV / Sales 2023 7,32x
Nbr of Employees 2 191
Free-Float 36,8%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 40,38 CNY
Average target price 105,04 CNY
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.-75.28%2 697
CSL LIMITED-1.96%88 546
SAMSUNG BIOLOGICS CO.,LTD.-10.63%39 998
BIOGEN INC.11.29%38 745
WUXI BIOLOGICS (CAYMAN) INC.-48.78%25 758
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 438